
Oncology NEWS International
- Oncology NEWS International Vol 8 No 8
- Volume 8
- Issue 8
NCI Discovers Gene Variations From Existing Databases
BETHESDA, Md-Using new computer software to “mine” existing databases, National Cancer Institute (NCI) scientists have discovered 10,435 possible new variations in human genes. The so-called single nucleotide polymorphisms, or SNPs, must still be validated, but NCI said each of the variations met statistical confidence levels of 0.99%.
BETHESDA, MdUsing new computer software to mine existing databases, National Cancer Institute (NCI) scientists have discovered 10,435 possible new variations in human genes. The so-called single nucleotide polymorphisms, or SNPs, must still be validated, but NCI said each of the variations met statistical confidence levels of 0.99%.
SNPs are considered likely influences on how fast a cancer grows and how well it responds to treatment. However, finding and understanding the variations has posed a considerable technical challenge, one eased somewhat by the special software used by the NCI scientists, noted team leader Kenneth Buetow, PhD.
Information on the new SNPs is available free to researchers on the NCIs Cancer Genome Anatomy Project website (
Articles in this issue
over 16 years ago
False positives frequent in CT lung cancer screening trialalmost 27 years ago
Stereotactic Core Biopsy Establishes Many Prognostic Factorsalmost 27 years ago
Breast Cancer Prevention With Tamoxifen Appears Cost-Effectivealmost 27 years ago
CPDR Unveils First Center Solely for Prostate Cancer Researchalmost 27 years ago
Going Beyond CHOP in Advanced Large-Cell Lymphomaalmost 27 years ago
Memorial Sloan-Kettering Opens Rockefeller Outpatient Pavilionalmost 27 years ago
Ernst Wynder, Pioneer in Preventive Medicinealmost 27 years ago
AHCPR Plans Health Care Market, Managed Care Research Centersalmost 27 years ago
NSAIDs May Protect Against Common GI Cancersalmost 27 years ago
Four Researchers Receive General Motors AwardsRelated Content


107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)





















































